Acurx Pharmaceuticals opened higher at $1.05, compared with its previous close of $1.03. In the last trading session, the stock traded between $0.98 and $1.06. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Acurx Pharmaceuticals is now worth
$ 0.99
Resulting in a loss of
$ 99.01 (99.01%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.04 (-3.59%)
Day High
$1.06
Day Low
$0.98
Day Open
$1.05
Prev Close
$1.03
Volume
1,44,449
1W Return
-4.98%
1M Return
-23.02%
3M Return
-32.91%
6M Return
-54.45%
1Y Return
-82.20%
Fundamentals
Market Cap ($ Mn)
6
PE Ratio
-
PB Ratio
0.83
PEG Ratio
-
ROE
-258.68%
ROCE
-262.75%
EPS (TTM)
$-0.48
Investment Returns
1 Week
-4.98%
1 Month
-23.02%
3 Months
-32.91%
6 Months
-54.45%
9 Months
-49.34%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
12Nov
Acurx Q3 loss widens to $2.6 million; HC Wainwright cuts PT to $11
Net loss widened to $2.6 million in Q3FY26 from $2 million in Q3FY25. HC Wainwright maintains Buy rating but cuts price target to $11 from $31. R&D expenses surged 175% YoY to $1.1 million due to CDI trial costs. Cash reserves increased to $9.7 million as of December 31, 2025.
Today
29Sep
Acurx Pharmaceuticals enrolls first patient in PATHFINDER clinical trial
1mo ago
18Sep
Acurx Pharmaceuticals Q2FY26 Results: Net loss widens 4.5% to $2.3 million
Net loss widened to $2.3 million in Q2FY26 from $2.2 million in Q2FY25. Cash reserves rose to $10.7 million, up from $7.6 million at Dec 31, 2025. R&D expenses jumped 120% YoY to $1.1 million due to clinical trial costs. FDA granted conditional acceptance for brand name CFezi for Ibezapolstat. Company secured funding for Pathfinder trial and one year of operations.
1mo ago
9Sep
Acurx Pharmaceuticals files prospectus for $1.5 million SEC offering
Acurx Pharmaceuticals filed an SEC prospectus for a $1.5 million offering. The filing represents a capital raising initiative by the company. No additional financial metrics or terms were disclosed in the source.
Acurx Pharmaceuticals Q2 EPS of $(0.53) missed the $(0.37) estimate by 43.24%. Losses increased 71.96% YoY from $(1.89), reflecting ongoing profitability challenges despite a reduction in absolute loss magnitude compared to the prior year period.
3mo ago
3Aug
Acurx Pharmaceuticals FDA open to single Phase 3 trial for ibezapolstat NDA
Acurx Pharmaceuticals, Inc. announced positive outcomes from its July 13, 2026 Type C Meeting with the FDA regarding ibezapolstat. The FDA is open to an NDA with one Phase 3 trial if data is robust; otherwise, a second trial per the April 2024 agreement is needed. Successful rCDI trial data will also support submission.
